Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
3.960
-0.040 (-1.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Senti Biosciences Revenue
In the year 2023, Senti Biosciences had annual revenue of $2.56M, down -40.25%.
Revenue (ttm)
$2.56M
Revenue Growth
-40.25%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
48
Market Cap
18.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
Dec 31, 2020 | 566.00K | 481.00K | 565.88% |
Dec 31, 2019 | 85.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SNTI News
- 2 months ago - Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - GlobeNewsWire
- 2 months ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Benzinga
- 2 months ago - Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - GlobeNewsWire
- 3 months ago - Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - GlobeNewsWire
- 6 months ago - Senti Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - GlobeNewsWire